Corcept Therapeutics Inc. (NASDAQ:CORT) shares fell 2.7% during mid-day trading on Friday . The company traded as low as $5.78 and last traded at $5.80, with a volume of 245,541 shares trading hands. The stock had previously closed at $5.96.

A number of research firms have issued reports on CORT. Zacks Investment Research upgraded Corcept Therapeutics from a “hold” rating to a “buy” rating and set a $6.75 target price on the stock in a research report on Tuesday. FBR & Co reiterated a “buy” rating on shares of Corcept Therapeutics in a research report on Saturday, June 4th.

The stock’s market cap is $629.13 million. The firm has a 50 day moving average of $5.61 and a 200-day moving average of $4.66.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings results on Tuesday, May 3rd. The company reported $0.02 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.01. The firm had revenue of $16.10 million for the quarter, compared to the consensus estimate of $16.32 million. On average, equities analysts anticipate that Corcept Therapeutics Inc. will post $0.04 EPS for the current year.

In other news, Director G Leonard Baker, Jr. purchased 100,000 shares of the business’s stock in a transaction dated Tuesday, May 10th. The stock was bought at an average price of $4.88 per share, for a total transaction of $488,000.00. Following the purchase, the director now owns 721,038 shares of the company’s stock, valued at $3,518,665.44. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

A hedge fund recently raised its stake in Corcept Therapeutics stock. Thornburg Investment Management Inc. increased its position in Corcept Therapeutics Inc. (NASDAQ:CORT) by 19.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 399,778 shares of the company’s stock after buying an additional 65,600 shares during the period. Thornburg Investment Management Inc. owned approximately 0.37% of Corcept Therapeutics worth $1,991,000 at the end of the most recent quarter.

Corcept Therapeutics Inc is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company’s focus is on those disorders that are associated with a steroid hormone cortisol. Elevated levels and abnormal release patterns of cortisol have been implicated in a range of human disorders.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.